rs886041310
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_030662.4(MAP2K2):c.183A>T(p.Lys61Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: not found (cov: 33)
Consequence
MAP2K2
NM_030662.4 missense
NM_030662.4 missense
Scores
7
9
3
Clinical Significance
Conservation
PhyloP100: 0.396
Genes affected
MAP2K2 (HGNC:6842): (mitogen-activated protein kinase kinase 2) The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 5 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.904
PP5
Variant 19-4117539-T-A is Pathogenic according to our data. Variant chr19-4117539-T-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 505022.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=1, Likely_pathogenic=1}.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MAP2K2 | ENST00000262948.10 | c.183A>T | p.Lys61Asn | missense_variant | 2/11 | 1 | NM_030662.4 | ENSP00000262948.4 | ||
MAP2K2 | ENST00000394867.9 | n.622A>T | non_coding_transcript_exon_variant | 1/10 | 5 | |||||
MAP2K2 | ENST00000599345.1 | n.380A>T | non_coding_transcript_exon_variant | 2/7 | 5 | |||||
MAP2K2 | ENST00000687128.1 | n.622A>T | non_coding_transcript_exon_variant | 1/7 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Cov.: 36
GnomAD4 exome
Cov.:
36
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:3
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 15, 2023 | Missense variants in this gene are often considered pathogenic (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25370473, 22753777, 19156172, 26399658, 22177953, 29493581, 34184824) - |
Noonan syndrome with multiple lentigines Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Service de Génétique Moléculaire, Hôpital Robert Debré | - | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 06, 2016 | Variant classified as Uncertain Significance - Favor Pathogenic. The p.Lys61Asn variant in MAP2K2 has not been previously reported in individuals with Noonan sp ectrum disorders or in large population studies. However, another variant (p.Lys 61Glu) at the same codon was identified in two probands with clinical features o f Cardio-facio-cutaneous syndrome, and a third variant (p.Lys61Thr) at the same codon was reported to have occurred de novo in one proband with a RASopathy (Nar umi 2007, Nava 2007, Wong Ramsey 2014), suggesting that changes at this position may not be tolerated. Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. In summar y, while there is some suspicion for a pathogenic role, the clinical significanc e of the p.Lys61Asn variant is uncertain. - |
Noonan syndrome 1 Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Molecular Genetics, Centre for Human Genetics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Pathogenic
D
Sift4G
Uncertain
T
Polyphen
D
Vest4
MutPred
Loss of ubiquitination at K61 (P = 0.0092);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at